Epigenetics and immunosuppression. Use of circulating histones and their post-translational modifications as biomarkers for diagnosis and prognosis in sepsis and septic shock. (Q3138351): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Sepsis has an incidence in Europe of 200-300 cases per 100,000 inhabitants/year. 2 % of hospitalised patients and 75 % of ICU patients develop a sepsis, of which 30 % evolve to septic shock (SS). In addition, many of the survivors develop an immunosuppression that makes them more sensitive to new infections and leads to an increase in long-term morbidity-mortality. Recently, it has been recommended the search for new sensitive and specific bioma...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Epigenetics and immunosuppression. Use of circulating histones and their post-translational modifications as biomarkers for diagnosis and prognosis in sepsis and septic shock. | |||
Revision as of 13:02, 12 October 2021
Project Q3138351 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Epigenetics and immunosuppression. Use of circulating histones and their post-translational modifications as biomarkers for diagnosis and prognosis in sepsis and septic shock. |
Project Q3138351 in Spain |
Statements
36,250.0 Euro
0 references
72,500.0 Euro
0 references
50.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER)
0 references
39°28'10.96"N, 0°22'34.82"W
0 references
46250
0 references
La sepsis tiene una incidencia en Europa de 200-300 casos por cada 100.000 habitantes/año. Un 2% de los pacientes hospitalizados y el 75% de los pacientes de UCI desarrollan una sepsis, de los que un 30% evolucionan a shock séptico (SS). Además, muchos de los supervivientes desarrollán una inmunosupresión que los hace más sensibles a nuevas infecciones y que produce un incremento de la morbi-mortalidad a largo término. Recientemente, se ha recomendado la búsqueda de nuevos biomarcadores sensibles y específicos para la sepsis basados en modificaciones epigenéticas. y en especial las histonas se han postulado como biomarcadores en enfermedades que cursan con hiperinflamación, trauma e infecciones. Por ello el objetivo de este proyecto es Identificar biomarcadores epigenéticos y desarrollar herramientas de diagnóstico y pronóstico para la clasificación de los fenotipos particulares de la sepsis que permitan predecir los estados de inmunosupresión. En este proyecto usaremos metodología basada en la espectrometría de masas para cuantificar los niveles de histonas circulantes y usarlas como biomarcadores en sepsis. Además, con estudios de ChIP-Seq y el análisis bioinformático contribuiremos a la comprensión de los mecanismos epigenéticos relacionados con la inmunosupresión en los supervivientes de un episodio de sepsis. (Spanish)
0 references
Sepsis has an incidence in Europe of 200-300 cases per 100,000 inhabitants/year. 2 % of hospitalised patients and 75 % of ICU patients develop a sepsis, of which 30 % evolve to septic shock (SS). In addition, many of the survivors develop an immunosuppression that makes them more sensitive to new infections and leads to an increase in long-term morbidity-mortality. Recently, it has been recommended the search for new sensitive and specific biomarkers for sepsis based on epigenetic modifications, and especially histones have been postulated as biomarkers in diseases with hyperinflammation, trauma and infections. Therefore, the objective of this project is to identify epigenetic biomarkers and to develop diagnostic and prognostic tools for the classification of particular sepsis phenotypes that allow predicting the immunosuppression states. In this project we will use methodology based on mass spectrometry to quantify the levels of circulating histones and use them as biomarkers in sepsis. In addition, with ChIP-Seq studies and bioinformatics we will contribute to the understanding of epigenetic mechanisms related to immunosuppression in survivors of a sepsis episode. (English)
12 October 2021
0 references
Valencia
0 references
Identifiers
PI16_01036
0 references